Search - tctmd.com

Displaying 41 - 60 of 307

Sort: Relevancy | Date

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

Presentation TCT 2021

Directional Versus Orbital Atherectomy of Femoropopliteal Artery Lesions: Angiographic and Intravascular Ultrasound Outcomes

Presenter: Anvar Babaev

November 06, 2021

Presentation TCT 2021

Determinants of Drug-coated Balloon Failure in Femoropopliteal Intervention. Insights From a Patient-level Pooled Analysis

Presenter: Prakash Krishnan

November 06, 2021

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

FDA Says Newer Paclitaxel Data Is ‘Comforting’ but Limited

News Daily News

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

L.A. McKeown

January 12, 2021

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

Presentation TCT 2020

Where Are We With the Data on Paclitaxel?

Presenter: Eric Secemsky

October 18, 2020

Presentation TCT 2020

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

Presenter: Andrew Holden

October 18, 2020

Presentation TCT 2020

TCT 366: Role of Embolic Protection Devices in Reducing Major Adverse Limb Events in Femoropopliteal Arterial Interventions in a Matched Cohort of Patients With Critical Limb Ischemia: Results From the XLPAD Registry.

Presenter: Qais Radaideh

October 14, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

Longer Patency, Fewer Repeat Procedures With Paclitaxel DCBs in Dialysis Patients

L.A. McKeown

August 21, 2020

News Daily News

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

L.A. McKeown

July 02, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Daily News

Recovered Paclitaxel PAD Data Shift the Mortality Picture

L.A. McKeown

May 14, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

Advertisement

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

Routine IVUS in Peripheral Interventions Supported by Small RCT

Directional Versus Orbital Atherectomy of Femoropopliteal Artery Lesions: Angiographic and Intravascular Ultrasound Outcomes

Determinants of Drug-coated Balloon Failure in Femoropopliteal Intervention. Insights From a Patient-level Pooled Analysis

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Where Are We With the Data on Paclitaxel?

ILLUMENATE: Four-Year Results With a Low-Dose Paclitaxel Drug-Coated Balloon in De Novo And Restenotic Femoropopliteal Lesions

TCT 366: Role of Embolic Protection Devices in Reducing Major Adverse Limb Events in Femoropopliteal Arterial Interventions in a Matched Cohort of Patients With Critical Limb Ischemia: Results From the XLPAD Registry.

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

Longer Patency, Fewer Repeat Procedures With Paclitaxel DCBs in Dialysis Patients

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Recovered Paclitaxel PAD Data Shift the Mortality Picture

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content